Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.
A number of human hematopoietic growth factors have been genetically cloned and recombinant proteins produced. Several phase I and II clinical trials have already been published and results from phase III studies are becoming available. The use of erythropoietin to alleviate chemotherapy-induced myelosuppression is being tested. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor have been extensively studied in patients receiving chemotherapy at standard or escalated doses and after bone marrow transplantation and appear to ameliorate chemotherapy-induced neutropenia and to speed bone marrow engraftment after high-dose cancer therapy. Interleukin-3 and interleukin-6 are quite early in their clinical development, but appear able to alleviate post-chemotherapy thrombocytopenia.
Catholic University of Louvain, Brussels, Belgium.
M
M
Symann
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D007239:Infections / Q000188:drug therapy / Q000209:etiology; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors